Kingsview Wealth Management LLC Purchases 34,924 Shares of Pfizer Inc. $PFE

Kingsview Wealth Management LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 19.2% in the 4th quarter, HoldingsChannel reports. The firm owned 216,415 shares of the biopharmaceutical company’s stock after acquiring an additional 34,924 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Pfizer were worth $5,389,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Kepler Cheuvreux Suisse SA bought a new position in shares of Pfizer during the third quarter valued at about $16,613,000. Money Concepts Capital Corp boosted its stake in shares of Pfizer by 29.9% during the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after purchasing an additional 57,188 shares during the period. Penn Davis Mcfarland Inc. boosted its stake in shares of Pfizer by 50.9% during the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after purchasing an additional 57,777 shares during the period. Mackenzie Financial Corp boosted its stake in shares of Pfizer by 119.6% during the third quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock valued at $79,157,000 after purchasing an additional 1,691,773 shares during the period. Finally, Pzena Investment Management LLC boosted its stake in shares of Pfizer by 0.9% during the third quarter. Pzena Investment Management LLC now owns 6,615,598 shares of the biopharmaceutical company’s stock valued at $168,565,000 after purchasing an additional 56,484 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.18 on Friday. Pfizer Inc. has a 1 year low of $23.06 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company’s 50-day moving average is $26.77 and its 200 day moving average is $26.28. The stock has a market capitalization of $149.23 billion, a P/E ratio of 19.99 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the previous year, the company earned $0.92 earnings per share. Pfizer’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s payout ratio is currently 131.30%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. BMO Capital Markets reissued an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Morgan Stanley upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Royal Bank Of Canada reaffirmed an “underperform” rating and set a $25.00 price objective on shares of Pfizer in a research note on Monday, April 20th. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Finally, HSBC upped their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.82.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a major global oncology collaboration with Innovent Biologics worth up to $10.5 billion. The deal gives Pfizer access to 12 early-stage cancer programs and expands its cancer pipeline, which investors may see as a long-term growth driver. Article Title
• Positive Sentiment: Pfizer reported seven-year follow-up data from its LORBRENA CROWN trial, showing the longest progression-free survival reported to date in advanced ALK-positive non-small cell lung cancer. Strong late-stage clinical evidence can support the drug’s commercial outlook and reinforce Pfizer’s oncology franchise. Article Title
• Positive Sentiment: Several reports highlighted progress in Pfizer’s clinical pipeline, including updates tied to lung cancer and obesity programs. Investors often reward pipeline milestones because they can improve future revenue potential and diversify growth beyond existing products. Article Title
• Neutral Sentiment: Commentary on insider activity suggested Pfizer insiders are not buying shares aggressively at current levels, but the article framed that as a lack of negative signal rather than a warning sign. This is more of a valuation/sentiment note than a direct catalyst. Article Title
• Neutral Sentiment: Additional items referenced early-stage trial updates and a real-world lung cancer study on dacomitinib. These are constructive for the pipeline, but they are still early and likely less material than the Innovent deal or the LORBRENA data. Article Title

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.